WO2008074032A1 - Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life - Google Patents
Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life Download PDFInfo
- Publication number
- WO2008074032A1 WO2008074032A1 PCT/US2007/087553 US2007087553W WO2008074032A1 WO 2008074032 A1 WO2008074032 A1 WO 2008074032A1 US 2007087553 W US2007087553 W US 2007087553W WO 2008074032 A1 WO2008074032 A1 WO 2008074032A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fviia
- life
- construct
- vivo half
- rfviia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07865679.0A EP2101821B1 (en) | 2006-12-15 | 2007-12-14 | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
PL07865679T PL2101821T3 (en) | 2006-12-15 | 2007-12-14 | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
CA2670618A CA2670618C (en) | 2006-12-15 | 2007-12-14 | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
BRPI0720282A BRPI0720282B8 (en) | 2006-12-15 | 2007-12-14 | protein construction, pharmaceutical composition, and kit |
DK07865679.0T DK2101821T3 (en) | 2006-12-15 | 2007-12-14 | Factor VIIA (poly) sialic acid conjugate with extended half-life in vivo |
AU2007333049A AU2007333049B2 (en) | 2006-12-15 | 2007-12-14 | Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life |
CN200780046301.6A CN101557830B (en) | 2006-12-15 | 2007-12-14 | There is the factor VIIa-Polysialic acid conjugate of the Half-life in vivo of prolongation |
JP2009541613A JP5876208B2 (en) | 2006-12-15 | 2007-12-14 | Factor VIIa- (poly) sialic acid conjugate with extended in vivo half-life |
ES07865679.0T ES2521490T3 (en) | 2006-12-15 | 2007-12-14 | Conjugate of factor VIIa - (poly) sialic acid with a prolonged half-life in vivo. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87521706P | 2006-12-15 | 2006-12-15 | |
US60/875,217 | 2006-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008074032A1 true WO2008074032A1 (en) | 2008-06-19 |
Family
ID=39119264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/087553 WO2008074032A1 (en) | 2006-12-15 | 2007-12-14 | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
Country Status (13)
Country | Link |
---|---|
US (4) | US8637007B2 (en) |
EP (3) | EP2101821B1 (en) |
JP (4) | JP5876208B2 (en) |
CN (3) | CN101557830B (en) |
AU (1) | AU2007333049B2 (en) |
BR (1) | BRPI0720282B8 (en) |
CA (1) | CA2670618C (en) |
DK (1) | DK2101821T3 (en) |
ES (2) | ES2521490T3 (en) |
HK (1) | HK1198172A1 (en) |
PL (1) | PL2101821T3 (en) |
PT (1) | PT2101821E (en) |
WO (1) | WO2008074032A1 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009000522A1 (en) * | 2007-06-26 | 2008-12-31 | Baxter International Inc. | Hydrolysable polymeric fmoc-linker |
WO2010045568A1 (en) * | 2008-10-17 | 2010-04-22 | Baxter International Inc. | Modified blood factors comprising a low degree of water soluble polymer |
WO2010014708A3 (en) * | 2008-08-01 | 2010-04-22 | Baxter International Inc. | Factor viii polymer conjugates |
WO2010102886A1 (en) | 2009-02-19 | 2010-09-16 | Novo Nordisk A/S | Modification of factor viii |
WO2011017055A3 (en) * | 2009-07-27 | 2011-04-07 | Baxter International Inc. | Blood coagulation protein conjugates |
US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
WO2011101267A1 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Conjugated fviii variants |
US8053561B2 (en) | 2006-03-31 | 2011-11-08 | Baxter International Inc. | Pegylated factor VIII |
EP2517714A1 (en) * | 2007-04-26 | 2012-10-31 | Inspiration Biopharmaceuticals, Inc. | Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same |
US8637007B2 (en) | 2006-12-15 | 2014-01-28 | Baxter International Inc. | Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
WO2014060397A1 (en) * | 2012-10-15 | 2014-04-24 | Novo Nordisk Health Care Ag | Factor vii conjugates |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8945897B2 (en) | 2010-07-26 | 2015-02-03 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
JP2015155469A (en) * | 2015-06-01 | 2015-08-27 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Fviii-polymer conjugates |
WO2015154139A1 (en) * | 2014-04-11 | 2015-10-15 | Csl Limited | Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor |
JP2015227385A (en) * | 2009-07-27 | 2015-12-17 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Blood coagulation protein conjugate |
US9370583B2 (en) | 2013-10-15 | 2016-06-21 | Novo Nordisk Healthcare Ag | Coagulation factor VII polypeptides |
US9474790B2 (en) | 2013-04-18 | 2016-10-25 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
US9486506B2 (en) | 2011-09-23 | 2016-11-08 | Novo Nordisk A/S | Glucagon analogues |
US9795683B2 (en) | 2009-07-27 | 2017-10-24 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
JP2018115170A (en) * | 2018-03-02 | 2018-07-26 | バクスアルタ ゲーエムベーハー | Factor fviii-polymer conjugates |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8759293B2 (en) | 2009-11-13 | 2014-06-24 | Grifols Therapeutics Inc. | von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
MX346271B (en) | 2010-07-30 | 2016-07-08 | Baxalta Inc | Nucleophilic catalysts for oxime linkage. |
US20150086524A1 (en) | 2012-04-16 | 2015-03-26 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
AU2013204754C1 (en) | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
AR099340A1 (en) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | CONJUGATES OF THE COAGULATION FACTOR IX |
HUE064463T2 (en) * | 2016-07-11 | 2024-03-28 | Opko Biologics Ltd | Long-acting coagulation factor vii and methods of producing same |
JP2022519586A (en) * | 2019-02-04 | 2022-03-24 | ゼネティック バイオサイエンシーズ インコーポレイテッド | How to Use Glycopolysial Oxidation Therapeutic Proteins |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020151471A1 (en) * | 2000-10-02 | 2002-10-17 | Pingel Hans Kurt | Factor VII glycoforms |
WO2004000366A1 (en) * | 2002-06-21 | 2003-12-31 | Novo Nordisk Health Care Ag | Pegylated factor vii glycoforms |
WO2004091499A2 (en) * | 2003-04-09 | 2004-10-28 | Neose Technologies, Inc. | Intracellular formation of peptide conjugates |
WO2006016168A2 (en) * | 2004-08-12 | 2006-02-16 | Lipoxen Technologies Limited | Sialic acid derivatives |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3487890A (en) | 1967-04-14 | 1970-01-06 | Boyles Bros Drilling Co | Core drilling system |
US3847890A (en) | 1971-11-01 | 1974-11-12 | A Green | Acidic monosaccharide-substituted proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
JPH0387173A (en) | 1987-09-10 | 1991-04-11 | Teijin Ltd | Preparation of human active natural type factor viii c and transformant using the same |
US5153265A (en) | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US4966999A (en) | 1988-06-07 | 1990-10-30 | Cytogen Corporation | Radiohalogenated compounds for site specific labeling |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
SE465222C5 (en) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | A recombinant human factor VIII derivative and process for its preparation |
SE466754B (en) | 1990-09-13 | 1992-03-30 | Berol Nobel Ab | COVALENT BINDING POLYMERS TO HYDROPHILIC SURFACES |
EP0513332A4 (en) | 1990-11-14 | 1993-03-17 | Cargill, Incorporated | Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins |
CA2101918A1 (en) | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
GB9112212D0 (en) * | 1991-06-06 | 1991-07-24 | Gregoriadis Gregory | Pharmaceutical compositions |
US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
WO1994005332A2 (en) | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
JP3905921B2 (en) | 1992-10-02 | 2007-04-18 | ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー | COMPOSITION CONTAINING COAGULATION FACTOR VIII, METHOD FOR PRODUCING THE SAME, AND METHOD FOR USING SURFACTANT AS STABILIATOR |
NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
FR2700268B1 (en) | 1993-01-13 | 1995-03-31 | Lvmh Rech | Cosmetic or pharmaceutical composition, especially dermatological, containing an extract of Vismia. |
AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
SE504074C2 (en) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Protein preparation for subcutaneous, intramuscular or intradermal administration |
WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
WO1996040731A1 (en) | 1995-06-07 | 1996-12-19 | Mount Sinai School Of Medicine Of The City University Of New York | Pegylated modified proteins |
SE9503380D0 (en) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
JP2001508783A (en) | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | PEGylation method |
EP0981548A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
US6673575B1 (en) | 1997-12-03 | 2004-01-06 | Roche Diagnostics Gmbh | Method for preparing polypeptides with appropriate glycosilation |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
CA2329768C (en) | 1998-04-27 | 2008-06-10 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
CN1330675A (en) | 1998-08-28 | 2002-01-09 | 格莱风科学公司 | Polyamide chains of precise length, methods to manufacture them and their conjugates with protein |
AU762616B2 (en) | 1998-10-16 | 2003-07-03 | Biogen Ma Inc. | Polymer conjugates of interferon beta-1a and uses |
DE19852729A1 (en) | 1998-11-16 | 2000-05-18 | Werner Reutter | Recombinant glycoproteins, processes for their preparation, medicaments containing them and their use |
PT2130554E (en) | 1999-02-22 | 2012-11-19 | Univ Connecticut | Albumin-free factor viii formulations |
US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
CN1309423C (en) | 1999-11-12 | 2007-04-11 | 马克西根控股公司 | Interferon gamma conjugates |
RU2278123C2 (en) | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Molecules similar to factor vii or viia |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
EP1280548B1 (en) | 2000-05-03 | 2013-12-11 | Novo Nordisk Health Care AG | Subcutaneous administration of coagulation factor VII |
EP1282693B1 (en) | 2000-05-03 | 2010-10-20 | Novo Nordisk Health Care AG | Human coagulation factor vii variants |
CN1434726A (en) | 2000-06-08 | 2003-08-06 | 拉卓拉药物公司 | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
PL204888B1 (en) | 2000-09-13 | 2010-02-26 | Novo Nordisk Healthcare Ag | Human coagulation factor vii variants |
DE60137525D1 (en) | 2000-10-16 | 2009-03-12 | Chugai Pharmaceutical Co Ltd | PEG-MODIFIED ERYTHROPOIETIN |
ES2432967T3 (en) | 2001-03-22 | 2013-12-05 | Novo Nordisk Health Care Ag | Coagulation Factor VII derivatives |
US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
EP2292271A3 (en) | 2001-10-10 | 2011-09-14 | BioGeneriX AG | Remodelling and glycoconjugation of an antibody |
KR100948532B1 (en) | 2001-11-07 | 2010-03-23 | 넥타르 테라퓨틱스 | Branched polymers and their conjugates |
EP1461445B1 (en) | 2001-11-28 | 2008-08-20 | Neose Technologies, Inc. | Glycoprotein remodeling using endoglycanases |
JP2005510229A (en) | 2001-11-28 | 2005-04-21 | ネオーズ テクノロジーズ, インコーポレイテッド | Remodeling of glycoproteins using amidases |
MXPA04012496A (en) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Pegylated factor vii glycoforms. |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
WO2004024776A1 (en) | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | Method of producing hydroxyalkyl starch derivatives |
US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
KR101025143B1 (en) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | Hydrolytically stable maleimide-terminated polymers |
AU2003300139B2 (en) | 2002-12-31 | 2008-08-28 | Nektar Therapeutics | Maleamic acid polymer derivatives and their bioconjugates |
HUE058897T2 (en) | 2003-02-26 | 2022-09-28 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
JP2007501811A (en) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Use of galactose oxidase for selective chemical conjugation of a retarder molecule to a protein of therapeutic interest. |
EP1653991A2 (en) | 2003-08-08 | 2006-05-10 | Fresenius Kabi Deutschland GmbH | Conjugates of a polymer and a protein linked by an oxime linking group |
US7807824B2 (en) | 2003-08-12 | 2010-10-05 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
WO2005016973A1 (en) | 2003-08-12 | 2005-02-24 | Lipoxen Technologies Limited | Polysialic acid derivatives |
EP1673453A2 (en) | 2003-10-07 | 2006-06-28 | Novo Nordisk Health Care AG | Hybrid molecules having factor vii/viia activity |
JP4738346B2 (en) | 2003-12-03 | 2011-08-03 | ノヴォ ノルディスク アー/エス | GlycoPEGylated factor IX |
KR101439880B1 (en) | 2004-01-08 | 2014-09-12 | 라티오팜 게엠베하 | O-linked glycosylation of peptides |
KR100651220B1 (en) | 2004-06-29 | 2006-11-29 | 씨제이 주식회사 | - - L-methionine producing microorganism and method of producing L-methionine using the microorganism |
AU2005261277A1 (en) | 2004-07-14 | 2006-01-19 | Mali Arel | Feeding bottles |
US20090292110A1 (en) | 2004-07-23 | 2009-11-26 | Defrees Shawn | Enzymatic modification of glycopeptides |
JP2008507990A (en) | 2004-08-02 | 2008-03-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Conjugate of FVII |
EP1824988B1 (en) | 2004-11-12 | 2017-04-19 | Bayer HealthCare LLC | Site-directed modification of fviii |
CN101163506B (en) * | 2004-12-27 | 2012-09-26 | 巴克斯特国际公司 | Polymer-von willebrand factor-conjugates |
EP1838332A1 (en) | 2005-01-06 | 2007-10-03 | Neose Technologies, Inc. | Glycoconjugation using saccharyl fragments |
WO2006090119A1 (en) * | 2005-02-23 | 2006-08-31 | Lipoxen Technologies Limited | Activated sialic acid derivatives for protein derivatisation and conjugation |
AU2006222187A1 (en) * | 2005-03-11 | 2006-09-14 | Fresenius Kabi Deutschland Gmbh | Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch |
JP5216580B2 (en) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | Glycopegylated factor IX |
WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
US20090017007A1 (en) | 2005-08-26 | 2009-01-15 | Maxygen Holdings Ltd. | Liquid factor vii composition |
US7390786B2 (en) | 2005-12-21 | 2008-06-24 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
BRPI0708832A2 (en) | 2006-03-31 | 2011-06-14 | Baxter Int | proteinacean construction |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US20090285780A1 (en) | 2006-05-24 | 2009-11-19 | Chyi Lee | Peg linker compounds and biologically active conjugates thereof |
JP2007319283A (en) * | 2006-05-31 | 2007-12-13 | Nippon Sherwood Medical Industries Ltd | Medical treatment bag |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
ES2565180T3 (en) | 2006-07-13 | 2016-04-01 | Serum Institute Of India Ltd, | Process for the preparation of high purity polysalic acid |
KR101400105B1 (en) | 2006-07-25 | 2014-06-19 | 리폭센 테크놀로지즈 리미티드 | N-terminal polysialylation |
WO2008057683A2 (en) | 2006-10-03 | 2008-05-15 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
CA2670618C (en) | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
US20100143326A1 (en) | 2007-01-03 | 2010-06-10 | Novo Nordisk Healthcare A/G | SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES |
WO2008119815A1 (en) | 2007-04-02 | 2008-10-09 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor ix |
US7700551B2 (en) | 2007-06-26 | 2010-04-20 | Baxter International Inc. | Hydrolysable polymeric FMOC-linker |
EP2173759A4 (en) | 2007-07-03 | 2014-01-29 | Childrens Hosp & Res Ct Oak | Oligosialic acid derivatives, methods of manufacture, and immunological uses |
ES2597849T3 (en) | 2007-10-09 | 2017-01-23 | Polytherics Limited | Novel conjugated proteins and peptides |
US20100286067A1 (en) | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
CN103497246B (en) | 2008-02-27 | 2016-08-10 | 诺沃—诺迪斯克有限公司 | The Factor VlII molecule puted together |
MX2010011672A (en) | 2008-04-24 | 2011-03-02 | Celtic Pharma Peg Ltd | Factor ix conjugates with extended half-lives. |
CN102083459A (en) | 2008-05-23 | 2011-06-01 | 诺沃-诺迪斯克保健股份有限公司 | Low viscosity compositions comprising a PEGylated GLA-domain containing protein |
JP2011520999A (en) | 2008-05-23 | 2011-07-21 | ノボ ノルディスク ヘルス ケア アーゲー | Formulation of peg-functionalized serine protease with high concentration of aromatic preservative |
CA2726942A1 (en) | 2008-06-04 | 2009-12-10 | Bayer Healthcare Llc | Fviii muteins for treatment of von willebrand disease |
KR101763559B1 (en) | 2008-07-21 | 2017-08-14 | 폴리테릭스 리미티드 | Novel Reagents and Method for Conjugating Biological Molecules |
EP2352515A4 (en) | 2008-11-03 | 2012-04-25 | Bayer Healthcare Llc | Method for the treatment of hemophilia |
EP2387413A4 (en) | 2009-01-19 | 2015-12-23 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase-cleavable bioprotective moiety |
EP2398822B1 (en) | 2009-02-19 | 2013-01-02 | Novo Nordisk A/S | Modification of factor viii |
US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
US20100330033A1 (en) | 2009-04-16 | 2010-12-30 | Nian Wu | Protein-carrier conjugates |
GB0908393D0 (en) | 2009-05-15 | 2009-06-24 | Almac Sciences Scotland Ltd | Labelling method |
ES2597954T3 (en) | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Blood coagulation protein conjugates |
KR101912335B1 (en) | 2009-07-27 | 2018-10-26 | 리폭센 테크놀로지즈 리미티드 | Glycopolysialylation of non-blood coagulation proteins |
JP2013500726A (en) | 2009-07-31 | 2013-01-10 | バイエル・ヘルスケア・エルエルシー | Modified factor IX polypeptides and uses thereof |
DE102009028526A1 (en) | 2009-08-13 | 2011-02-24 | Leibniz-Institut Für Polymerforschung Dresden E.V. | Process for the modification and functionalization of saccharides |
EP2480578A4 (en) | 2009-09-25 | 2013-04-17 | Vybion Inc | Polypeptide modification |
WO2011064247A1 (en) | 2009-11-24 | 2011-06-03 | Novo Nordisk Health Care Ag | Method of purifying pegylated proteins |
JP5914363B2 (en) | 2010-02-16 | 2016-05-11 | ノヴォ ノルディスク アー/エス | Factor VIII molecule with reduced VWF binding |
GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
WO2012068134A1 (en) | 2010-11-15 | 2012-05-24 | Biogen Idec Inc. | Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography |
MY180714A (en) | 2011-07-08 | 2020-12-07 | Bioverativ Therapeutics Inc | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
-
2007
- 2007-12-14 CA CA2670618A patent/CA2670618C/en active Active
- 2007-12-14 AU AU2007333049A patent/AU2007333049B2/en active Active
- 2007-12-14 EP EP07865679.0A patent/EP2101821B1/en active Active
- 2007-12-14 EP EP17196565.0A patent/EP3323430A1/en not_active Withdrawn
- 2007-12-14 CN CN200780046301.6A patent/CN101557830B/en active Active
- 2007-12-14 WO PCT/US2007/087553 patent/WO2008074032A1/en active Application Filing
- 2007-12-14 ES ES07865679.0T patent/ES2521490T3/en active Active
- 2007-12-14 JP JP2009541613A patent/JP5876208B2/en active Active
- 2007-12-14 BR BRPI0720282A patent/BRPI0720282B8/en active IP Right Grant
- 2007-12-14 CN CN201610304880.0A patent/CN105838699A/en active Pending
- 2007-12-14 DK DK07865679.0T patent/DK2101821T3/en active
- 2007-12-14 PL PL07865679T patent/PL2101821T3/en unknown
- 2007-12-14 US US11/956,634 patent/US8637007B2/en active Active
- 2007-12-14 PT PT78656790T patent/PT2101821E/en unknown
- 2007-12-14 CN CN201310698649.0A patent/CN103804489A/en active Pending
- 2007-12-14 EP EP12004951.5A patent/EP2532369B1/en active Active
- 2007-12-14 ES ES12004951.5T patent/ES2655639T3/en active Active
-
2010
- 2010-09-08 US US12/877,425 patent/US20110064714A1/en not_active Abandoned
-
2012
- 2012-12-25 JP JP2012281272A patent/JP2013060462A/en active Pending
-
2013
- 2013-12-20 US US14/136,328 patent/US20140186323A1/en not_active Abandoned
-
2014
- 2014-11-19 HK HK14111668.2A patent/HK1198172A1/en unknown
-
2015
- 2015-06-16 JP JP2015121340A patent/JP2015163650A/en not_active Withdrawn
- 2015-11-19 US US14/946,286 patent/US10251941B2/en active Active
-
2017
- 2017-05-29 JP JP2017105504A patent/JP2017141305A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020151471A1 (en) * | 2000-10-02 | 2002-10-17 | Pingel Hans Kurt | Factor VII glycoforms |
WO2004000366A1 (en) * | 2002-06-21 | 2003-12-31 | Novo Nordisk Health Care Ag | Pegylated factor vii glycoforms |
WO2004091499A2 (en) * | 2003-04-09 | 2004-10-28 | Neose Technologies, Inc. | Intracellular formation of peptide conjugates |
WO2006016168A2 (en) * | 2004-08-12 | 2006-02-16 | Lipoxen Technologies Limited | Sialic acid derivatives |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071726B2 (en) | 2006-03-31 | 2011-12-06 | Baxter International Inc. | Factor VIII polymer conjugates |
US8071725B2 (en) | 2006-03-31 | 2011-12-06 | Baxter International Inc. | Factor VIII polymer conjugates |
US8003760B2 (en) | 2006-03-31 | 2011-08-23 | Baxter International Inc. | Factor VIII polymer conjugates |
US11020458B2 (en) | 2006-03-31 | 2021-06-01 | Takeda Pharmaceutical Company Limited | Factor VIII polymer conjugates |
US8071724B2 (en) | 2006-03-31 | 2011-12-06 | Baxter International Inc. | Factor VIII polymer conjugates |
US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US7985838B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
US8071728B2 (en) | 2006-03-31 | 2011-12-06 | Baxter International Inc. | Factor VIII polymer conjugates |
US8071727B2 (en) | 2006-03-31 | 2011-12-06 | Baxter International Inc. | Factor VIII polymer conjugates |
US8067543B2 (en) | 2006-03-31 | 2011-11-29 | Baxter International Inc. | Factor VIII polymer conjugates |
US8053561B2 (en) | 2006-03-31 | 2011-11-08 | Baxter International Inc. | Pegylated factor VIII |
US8637007B2 (en) | 2006-12-15 | 2014-01-28 | Baxter International Inc. | Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life |
EP2517714A1 (en) * | 2007-04-26 | 2012-10-31 | Inspiration Biopharmaceuticals, Inc. | Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same |
WO2009000522A1 (en) * | 2007-06-26 | 2008-12-31 | Baxter International Inc. | Hydrolysable polymeric fmoc-linker |
US8445544B2 (en) | 2007-06-26 | 2013-05-21 | Baxter International Inc. | Hydrolysable polymeric FMOC-linker |
JP2013500238A (en) * | 2008-08-01 | 2013-01-07 | バクスター・インターナショナル・インコーポレイテッド | Factor FVIII polymer conjugate |
WO2010014708A3 (en) * | 2008-08-01 | 2010-04-22 | Baxter International Inc. | Factor viii polymer conjugates |
CN102112156B (en) * | 2008-08-01 | 2015-01-28 | 巴克斯特国际公司 | Factor VIII polymer conjugates |
AU2009305612B2 (en) * | 2008-10-17 | 2015-05-21 | Takeda Pharmaceutical Company Limited | Modified blood factors comprising a low degree of water soluble polymer |
JP2012505917A (en) * | 2008-10-17 | 2012-03-08 | バクスター・インターナショナル・インコーポレイテッド | Modified blood factor containing low water-soluble polymer |
EP3437661A1 (en) * | 2008-10-17 | 2019-02-06 | Baxalta GmbH | Modified blood factors comprising a low degree of water soluble polymer |
WO2010045568A1 (en) * | 2008-10-17 | 2010-04-22 | Baxter International Inc. | Modified blood factors comprising a low degree of water soluble polymer |
WO2010102886A1 (en) | 2009-02-19 | 2010-09-16 | Novo Nordisk A/S | Modification of factor viii |
US9731024B2 (en) | 2009-07-27 | 2017-08-15 | Baxalta Incorporated | Nucleophilic catalysts for oxime linkage |
JP2015227385A (en) * | 2009-07-27 | 2015-12-17 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Blood coagulation protein conjugate |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
WO2011017055A3 (en) * | 2009-07-27 | 2011-04-07 | Baxter International Inc. | Blood coagulation protein conjugates |
JP7071093B2 (en) | 2009-07-27 | 2022-05-18 | 武田薬品工業株式会社 | Blood coagulation protein complex |
US11564992B2 (en) | 2009-07-27 | 2023-01-31 | Takeda Pharmaceutical Company Limited | Nucleophilic catalysts for oxime linkage |
JP2013500343A (en) * | 2009-07-27 | 2013-01-07 | バクスター・インターナショナル・インコーポレイテッド | Blood coagulation protein complex |
JP2021042244A (en) * | 2009-07-27 | 2021-03-18 | バクサルタ インコーポレイテッド | Blood coagulation protein conjugates |
US10772968B2 (en) | 2009-07-27 | 2020-09-15 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
US11040109B2 (en) | 2009-07-27 | 2021-06-22 | Takeda Pharmaceutical Company Limited | Blood coagulation protein conjugates |
US10576160B2 (en) | 2009-07-27 | 2020-03-03 | Baxalta Incorporated | Nucleophilic catalysts for oxime linkage |
US10414793B2 (en) | 2009-07-27 | 2019-09-17 | Baxalta Incorporated | Nucleophilic catalysts for oxime linkage |
US10350301B2 (en) | 2009-07-27 | 2019-07-16 | Baxalta Incorporated | Blood coagulation protein conjugates |
US8637640B2 (en) | 2009-07-27 | 2014-01-28 | Baxter International Inc. | Blood coagulation protein conjugates |
JP2018035192A (en) * | 2009-07-27 | 2018-03-08 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Blood coagulation protein conjugates |
US9492555B2 (en) | 2009-07-27 | 2016-11-15 | Baxalta Incorporated | Nucleophilic catalysts for oxime linkage |
EP3093029A1 (en) * | 2009-07-27 | 2016-11-16 | Baxalta GmbH | Blood coagulation protein conjugates |
US9795683B2 (en) | 2009-07-27 | 2017-10-24 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
US9018166B2 (en) | 2010-02-16 | 2015-04-28 | Novo Nordisk A/S | Conjugated FVIII variants |
WO2011101267A1 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Conjugated fviii variants |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8945897B2 (en) | 2010-07-26 | 2015-02-03 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
US9486506B2 (en) | 2011-09-23 | 2016-11-08 | Novo Nordisk A/S | Glucagon analogues |
US9486505B2 (en) | 2011-09-23 | 2016-11-08 | Novo Nordisk A/S | Glucagon analogues |
US10179905B2 (en) | 2012-10-15 | 2019-01-15 | Novo Nordisk Health Care Ag | Factor VII conjugates |
WO2014060397A1 (en) * | 2012-10-15 | 2014-04-24 | Novo Nordisk Health Care Ag | Factor vii conjugates |
US9474790B2 (en) | 2013-04-18 | 2016-10-25 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
US9751927B2 (en) | 2013-04-18 | 2017-09-05 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
US9371370B2 (en) | 2013-10-15 | 2016-06-21 | Novo Nordisk Healthcare Ag | Coagulation factor VII polypeptides |
US9370583B2 (en) | 2013-10-15 | 2016-06-21 | Novo Nordisk Healthcare Ag | Coagulation factor VII polypeptides |
WO2015154139A1 (en) * | 2014-04-11 | 2015-10-15 | Csl Limited | Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor |
JP2017513831A (en) * | 2014-04-11 | 2017-06-01 | シーエスエル、リミテッド | HALF-LIFE EXTENDED Factor FVIIA Protein for the Prevention and Treatment of Bleeding and its Dosing Regimens |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
JP2015155469A (en) * | 2015-06-01 | 2015-08-27 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Fviii-polymer conjugates |
JP2018115170A (en) * | 2018-03-02 | 2018-07-26 | バクスアルタ ゲーエムベーハー | Factor fviii-polymer conjugates |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10251941B2 (en) | Factor VIIa-polysialic acid conjugates having prolonged in vivo half-life | |
DK2459224T3 (en) | Blodstørkningsproteinkonjugater | |
US11040109B2 (en) | Blood coagulation protein conjugates | |
JP2011507919A (en) | Modified factor IX |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780046301.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07865679 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2670618 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007333049 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3494/DELNP/2009 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2009541613 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007865679 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007333049 Country of ref document: AU Date of ref document: 20071214 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0720282 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090612 |